Beyond Basal Insulin in Type 2 Diabetes
Several studies presented at ADA 2016 discussed going beyond basal insulin treatments for patients with type 2 diabetes.
Several studies presented at the 2016 American Diabetes Association annual meeting dealt with going beyond basal insulin treatments for type 2 diabetes mellitus (DM) patients. Here are the highlights from four abstracts on treatment intensification options.
Beyond Basal Insulin in Type 2 Diabetes. from ADA Scientific Sessions
Insulin Degludec/Liraglutide vs. Insulin Glargine. Abstract link.
Patients with T2DM treated with insulin degludec/liraglutide have a greater chance of reaching glycemic targets.
Insulin degludec/liraglutide led to better glycemic control.
Faster-acting Insulin Aspart. Abstract link.
Faster-acting insulin aspart improves postprandial glycemic control in uncontrolled T2DM.
Faster aspart effectively improved 1-hour postprandial plasma glucose control.
Faster-acting Insulin vs. Basal Insulin. Abstract link.
Adding faster-acting insulin aspart to basal insulin significantly improved glycemic control.
Faster aspart in a basal-bonus regimen provided superior glycemic control versus basal insulin only.
Insulin Glargine/Lixisenatide vs. Insulin Glargine. Abstract link.
A fixed-ratio combination of insulin glargine/lixisenatide is more effective and safer than insulin glargine in patients with T2DM.
After a 6-week run-in phase, insulin glargine was introduced or optimized.
Glargine/lixisenatide showed superior glycemic control to insulin glargine.
